Osteoporosis vs Osteomalacia and Rickets

Why Alendronate is correct

• This patient has a T-score of -2.8, meeting the treatment threshold of T-score below -2.5 at any site.
• FRAX shows a 10-year major osteoporotic fracture probability of 18% (approaching but not exceeding the 20% threshold) and hip fracture probability of 5% (above the 3% threshold), further supporting treatment.
• Oral bisphosphonates (alendronate 70mg weekly or risedronate 35mg weekly) are the established first-line pharmacologic therapy for osteoporosis.
• Efficacy of bisphosphonates: reduces vertebral fractures 50%, hip fractures 40-50%, non-vertebral fractures 25%.

Why the others are wrong

• Teriparatide — anabolic agent reserved for very high-risk patients (T-score below -3.0, severe or multiple fractures, or failure of antiresorptive therapy); not first-line in this patient without prior fractures (premature escalation).
• Calcium and vitamin D alone — adjuncts to any bone-active therapy but insufficient as standalone treatment for established osteoporosis (undertreatment trap).
• Denosumab — appropriate for bisphosphonate intolerance, chronic kidney disease (CKD), or high-risk patients; not the first-line choice when oral bisphosphonates are tolerated (right-concept-wrong-line).

Additional high-yield points

• Osteoporosis treatment indications: (1) T-score below -2.5 at any site; (2) T-score -1.0 to -2.5 with FRAX 10-year hip fracture probability above 3% or major osteoporotic fracture above 20%; (3) Prior fragility fracture.
• Zoledronic acid (annual IV infusion): alternative for GI intolerance or adherence issues.
• Calcium 1200mg/day plus vitamin D 800-1000 IU/day: adjuncts with any bone-active therapy.
• Abaloparatide: another anabolic option alongside teriparatide for very high-risk patients.

Why Exclusive breastfeeding, no vitamin D is correct

• The clinical and biochemical picture (frontal bossing, rachitic rosary, frayed and cupped metaphyses, low phosphate, high alkaline phosphatase, high PTH) is nutritional vitamin D-deficiency rickets, the most common cause worldwide.
• Human breast milk contains very little vitamin D, so an exclusively breastfed infant given no supplement is at the highest risk. The AAP recommends 400 IU/day of vitamin D for all infants from birth precisely to prevent this.
• Among the listed options, this is the dominant, modifiable exposure driving defective growth-plate mineralization in this child.

Why the others are wrong

• Delayed introduction of solid foods — Complementary foods supply very little vitamin D, so their timing is at most a minor contributor; the mineralization defect here is driven by the absent vitamin D supplement, not by when solids were started.
• Family history of adult-onset osteoporosis — Osteoporosis is reduced bone mass with normal mineralization (normal calcium, phosphate, and alkaline phosphatase) and is unrelated to the vitamin D-dependent mineralization defect of rickets.
• Cow's milk protein allergy during infancy — This causes GI symptoms and, if it leads to restricted intake, only a minor indirect effect; it is not an established strong driver of rickets compared with the absence of vitamin D in an exclusively breastfed infant.